Decoding the Clinical Impact of Host and Microbial Intestinal Proteomic Landscape in Crohn's Disease

Exclusion Criteria

• •Established diagnosis of inflammatory bowel disease (IBD) with prior treatment.
• •Chronic gastro-intestinal disorder (e.g. celiac disease, eosinophilic esophagitis, collagenous gastritis, autoimmune gastritis, etc.).
• •Type 1 or type 2 diabetes mellitus.
• •Past or present history of malignancy.
• •BMI \> 30 (kg/m2)
• •Use of systemic antibiotics or probiotics 2 months prior to enrolment.
• •Use of steroids 2 months prior to enrolment (not including a short course of topical steroidal therapy).
• •Any previous major gastric or intestinal surgery.
• •Suspected or proven extensive involvement of non-ileal small intestine or colon, or significant perianal disease.
• •Significantly stricturing or penetrating (fistulizing) disease at presentation.
• •Chronic treatment with any oral/systemic immunosuppressive or anti-inflammatory drugs (e.g. steroids, 5-aminosalicylic acid, immunomodulators, biologics, etc.). Patients receiving these drugs as inhalers/creams/ointments should not be excluded from the study.
• •Primary immunodeficiency.
• •Pregnancy or breastfeeding in the last 6 months.
• •Serious medical conditions that may alter the gut microbiome composition, based on investigators judgement (for example primary immunodeficiency, autoimmune disorder, or rheumatologic disease).